Plain language summary
======================

**Why was the study done?** We assessed whether the effect of non-liver disease on survival in patients with liver disease scarring (called cirrhosis) is better captured by a cirrhosis-specific measure (the CirCom score) than by a generic measure (the Charlson Comorbidity Index \[CCI\]).

**What did the researchers do and find?** The CirCom score was better able to predict patients' survival times than the CCI, particularly in younger patients, patients with less severe cirrhosis, and patients whose cirrhosis was due to alcohol.

**What do these results mean?** This paper showed that the CirCom score is better than the CCI at describing the survival of English patients with liver cirrhosis. It also demonstrated the importance of accounting for non-liver disease in patients with liver cirrhosis.

Introduction
============

Patients with cirrhosis have a high mortality.[@b1-clep-10-107] Their high mortality is partly due to comorbidity,[@b2-clep-10-107] so adjustment for differences in the burden of comorbidity is important in studies that compare mortality among these patients. This is similar to what has been shown in end-stage renal failure, heart failure, and chronic obstructive pulmonary disease (COPD).[@b3-clep-10-107]--[@b5-clep-10-107] For cirrhosis, Jepsen et al have developed a comorbidity score (CirCom) within a Danish cohort of patients with liver cirrhosis and shown it to be an improvement on the existing Charlson comorbidity score.[@b6-clep-10-107] However, the accompanying commentary recommended further external validation that included calculation of absolute risks, as well as discrimination and model fit.[@b7-clep-10-107]

The most frequently validated method to date is the secondary care-derived CCI, published in 1987,[@b8-clep-10-107] developed using hospital chart data of medical inpatients to predict mortality in the 1-year postdischarge and validated in a cohort of breast cancer inpatients. However, this score assessed all medical inpatients rather than those with specific disease, thus failing to recognize that the prognostic effect of a specific comorbid disease (eg, COPD) might depend on the index disease (eg, ischemic heart disease versus cirrhosis). Furthermore, the management and prognosis of various diseases have changed greatly over the last two decades altering what is relevant to be contained in a score. In contrast, CirCom was derived specifically for cirrhotic patients and reassessed which comorbidities were associated with mortality in this context. It is simpler in that it includes less comorbidities overall compared to the CCI, but with some different comorbidities such as substance abuse (other than alcohol use) and epilepsy.[@b6-clep-10-107] We have previously extracted a validated and well-described cohort of cirrhotic patients with mixed etiology from linked primary care, secondary care, and death registry data within the Clinical Practice Research Datalink (CPRD).[@b9-clep-10-107] The purpose of this validation study of the CirCom score within this English cohort is to assess the performance of CirCom compared to the CCI in predicting mortality. By doing this assessment, we hope to provide evidence for its use (or nonuse) as the preferred measure of comorbidity adjustment in future population-based observational studies on cirrhosis mortality.

Materials and methods
=====================

Dataset
-------

The CPRD consists of linked English Hospital Episodes Statistics data, primary care data, and the Office of National Statistics (ONS) death register. For this study, these data have linked records of all primary care events, hospital admissions, and causes of death from April 1997 to August 2010 for 3% of the English population (244 primary care practices).

Population
----------

The cirrhosis cohort we used is one we have previously defined from the January 2011 static version of the CPRD (ISAC approved protocol number 09_065RA_4 and updated approval for this validation study 16_161).[@b9-clep-10-107] It consists of 5118 patients who were ≥18 years and had a diagnostic code for cirrhosis or a therapeutic code for cirrhosis, esophageal varices, or portal hypertension within either primary care or secondary care data within the CPRD between January 1, 1998 and December 31, 2009. These dates define the period when the linked data were available at the time of the initial study. The presence of cirrhosis was validated using secondary care, death registry, and free text data.[@b1-clep-10-107] The study population was restricted to the 244 practices with the primary and secondary care linkages available within the January 2011 static version of the CPRD. For this cirrhosis cohort, the patient characteristics, etiology of the cirrhosis (alcohol, viral/autoimmune/metabolic, or unknown), cause of death, and 5-year survival have been well described.[@b1-clep-10-107],[@b10-clep-10-107] The observation period for patients within this cohort commenced on the latest of 1) 1 year after each patient's current registration date with an eligible practice, 2) the date that their practice's data were up to research standard, or 3) January 1, 1998, when the linkage of the CPRD to secondary care data was first available. The 1-year cutoff following registration was used to avoid including potential prevalent cases who were diagnosed before they were observable in the dataset. The period of observation in this cohort terminated for each patient on the earliest of 1) the date of their death, 2) the date the patient left the practice, 3) their practice's last data collection date, 4) the last date of the available linkage to secondary care (at the time of the study derivation) which was December 31, 2009. Within this observation period, the start of each patient's follow-up was defined as his or her first Read or ICD 10 code for cirrhosis within the observation period. Patients with a diagnosis of cirrhosis before the observation period were excluded as the CirCom score was defined from comorbidity present at the time of diagnosis of cirrhosis. Follow-up for each patient ended at the end of the observation period described above.

Ethics
------

The CPRD has obtained ethical approval from the National Research Ethics Service Committee (NRECS) for all purely observational research using anonymized CPRD data. Studies which do not include patient involvement are reviewed for scientific quality by the Independent Scientific Advisory Committee for the Medicines and Healthcare Products Regulatory Agency database research. Regulatory approval for this study was obtained under approval 16_161.

Sample size
-----------

Studies modeling required sample sizes for complex discriminatory models have indicated that a study like ours requires at least 500 deaths, and ideally 1000.[@b11-clep-10-107] Two thousand five hundred sixty-four deaths occurred within our liver cirrhosis cohort within the follow-up time providing sufficient power overall. Within the stratified analysis, there were more than 500 deaths in each of the etiology groups when defined as Viral/Autoimmune/Metabolic, Alcoholic, or Unspecified, and within each of the age categories defined below.

Comorbidity scores
------------------

We defined the CirCom score as described by Jepsen et al.[@b6-clep-10-107] This score defines seven different weighted categories using ICD 10 codes. We also defined the CCI[@b8-clep-10-107] to provide a comparison similar to Jepsen et al's paper. We used the Read and ICD 10 codes for the individual comorbidities that we have previously defined for calculating the CCI in linked primary and secondary care data within the CPRD.[@b12-clep-10-107] The Read codes for these comorbidities were also used to define the comorbidities for the CirCom score, apart from substance abuse, epilepsy, and COPD. For the latter two of these categories, we used published code lists from [www.clinicalcodes.org](http://www.clinicalcodes.org),[@b13-clep-10-107],[@b14-clep-10-107] and for substance abuse, the Read codes are listed in [Table S1](#SD3-clep-10-107){ref-type="supplementary-material"}. All comorbidities were defined using all diagnoses coded in the 5 years prior to the cirrhosis diagnosis date as was done in Jepsen et al's original paper.[@b6-clep-10-107]

Other covariates included etiology, cirrhosis stage, year of follow-up, socioeconomic status, age, and gender. For the stratified analysis, we used the age bands we published in our original cohort (\<45, 45--54, 55--64, 65--74, \>75 years).[@b10-clep-10-107] Etiology was defined using the previously defined groups in the cohort as Alcoholic, Viral/Autoimmune/Metabolic, or Unspecified. Cirrhosis stage was defined as compensated or decompensated using the Baveno IV criteria already defined in the cohort.[@b1-clep-10-107] Socioeconomic status was defined by quintile of deprivation as measured by the English Indices of Multiple Deprivation 2010.[@b15-clep-10-107] Each year of follow-up from the first to the fifth year after cirrhosis diagnosis was defined, similar to our previously published work on comorbidity scores.[@b12-clep-10-107] Finally, we used cirrhosis and non-cirrhosis death outcomes as already defined in this cohort from previous work on cause of death from the linked ONS Death Registry.[@b10-clep-10-107] Specifically, we categorized deaths using the main ICD 10 chapter headings of K70--K77, C22, I85, I864, and I982 as liver related. This definition included bleeding from gastric and esophageal varices and hepatocellular carcinoma. All other ICD 10 codes were categorized as a non-liver death.

Statistical analysis
--------------------

We described the cohort characteristics for each covariate to allow a comparison with numbers and proportions with the Danish Development cohort. We then fitted a Cox proportional hazards model including age, gender, and either the CCI as a categorical variable or the CirCom score as a categorical variable as in the Jepsen paper. To compare how well the Charlson and CirCom score models fitted the data, we calculated the Bayesian information criterion (BIC). This measure penalizes the likelihood of the model for the number of parameters it includes, and the model with the smaller BIC value is more likely to have a better fit. Discrimination was measured using the Harrell's C statistic, with 95% CIs calculated using the somersD command in Stata.[@b16-clep-10-107] We calculated the predicted absolute 1-year mortality risk from each model using cumulative incidence functions. These absolute predicted mortality risks were used to classify patients into 1-year mortality probabilities of ≤20%, 21%--50%, and ≥51% to allow the net reclassification index (NRI) to be calculated. These were the categories used to assess the development of the CirCom score in the Danish cohort and were chosen to be clinically relevant.[@b6-clep-10-107]

To assess the calibration of the two scores, the observed 1-year mortality, computed using the Kaplan--Meier method, was plotted against the 1-year mortality predicted by the Cox model.[@b17-clep-10-107] In addition, a decision curve analysis was performed assessing the net benefit of using each score compared to not using a score. The net benefit is calculated as the difference between the true positives (proportion of patients whose predicted risk was over a particular threshold who also died within 1 year of follow-up) and the false positives (proportion of patients whose predicted risk was over a particular threshold who did not die within 1 year of follow-up), for thresholds of predicted risk from 0% to 100%.[@b18-clep-10-107]

A stratified analysis was then performed to assess the models' discrimination by age, gender, socioeconomic status, cirrhosis etiology, cirrhosis stage, and follow-up year as defined above. A final analysis assessed the models' discrimination in predicting liver-related death and non-liver-related death separately.

Results
=======

Validation population characteristics
-------------------------------------

The validation cirrhosis cohort from the CPRD had fewer patients than that used in Denmark for the score's development and a shorter median follow-up time (1.9 years compared to 2.8 years, respectively), but a similar median age (59 years compared to 58 years, respectively). The CPRD cohort had a lower proportion with alcohol as an etiology, a lower proportion of men, and a lower mortality. This was despite a higher proportion of patients in the CPRD who had a comorbidity that contributed to the Charlson or CirCom score ([Table 1](#t1-clep-10-107){ref-type="table"}).

Overall performance of comorbidity scores
-----------------------------------------

The full models are shown for comparison in [Table 2](#t2-clep-10-107){ref-type="table"}. The CirCom score provided a better model fit than the CCI with an improvement in the BIC ([Table 2](#t2-clep-10-107){ref-type="table"}).

Measures of discrimination of the CCI and CirCom score models are shown in [Table 3](#t3-clep-10-107){ref-type="table"} compared to models with age and sex alone. Both scores showed an improvement when compared to age and sex alone with a small improvement in the C statistic from the model using the CirCom score compared to the CCI. This was also reflected in the 1.5% improvement of the CirCom score over the CCI in classifying 1-year mortality as measured by the categorical NRI (see [Table 3](#t3-clep-10-107){ref-type="table"}). The addition of a covariate for decompensated or compensated liver disease further increased the discrimination of the model containing the CirCom score (C=0.67, 95% confidence interval \[0.66--0.68\]). Calibration was similar between the two scores ([Figure S1](#SD1-clep-10-107){ref-type="supplementary-material"}). The decision curve analysis showed similar results for both scores, with a net benefit in true over false positives when the threshold used for the predicted risk of 1-year mortality was between 20% and 60% for both the CCI and the CirCom score ([Figure S2](#SD2-clep-10-107){ref-type="supplementary-material"}).

To assess whether the differences in performance were due to difference in numbers of parameters, we reassessed the CCI score collapsed to 0, 1, 2, 3, 4, and 5 or more. This reduced the BIC for the CCI to 40,369, but this was still greater than the BIC for the CirCom score (which remained the better fit). The discrimination for the CCI with only six parameters was not altered (C statistic=0.62 \[0.61--0.63\]).

Stratified analysis
-------------------

The CirCom score conferred a slight improvement in discrimination over the CCI in younger age groups, particularly in the \<45-year-old age group ([Table 4](#t4-clep-10-107){ref-type="table"}). Among the subgroups defined by cirrhosis etiology, the difference between the CCI and the CirCom score was most notable in the subgroup with alcoholic cirrhosis ([Table 5](#t5-clep-10-107){ref-type="table"}). Both comorbidity scores performed better in those with autoimmune, viral, metabolic, or unknown causes, which reflected the older mean age in these groups and resultant higher prevalence of comorbidity. There was also a slight improvement in discrimination of the CirCom score over the CCI in those with compensated cirrhosis at presentation, but not in those with decompensated cirrhosis. The CirCom score performed better than the CCI in the first year of follow-up with similar discrimination in the subsequent years ([Table 6](#t6-clep-10-107){ref-type="table"}). Discrimination reduced with increasing deprivation, but there was less of a reduction for the CirCom score ([Table S2](#SD4-clep-10-107){ref-type="supplementary-material"}).

Both comorbidity scores had identically poor discrimination for liver-related death and identically good discrimination for non-liver-related death. The inclusion of a measure of decompensation improved the discrimination of a model with either score for liver-related death ([Table 7](#t7-clep-10-107){ref-type="table"}).

Discussion
==========

The CirCom score provided a small improvement in performance over the CCI when used to predict mortality in a large, population-based cohort of patients with cirrhosis of mixed etiology. Both scores showed good discriminative ability to predict deaths not related to the liver, which were almost half of the deaths, but poor ability to predict deaths related to the liver. However, the purpose of a comorbidity score is to adjust for factors other than the severity of cirrhosis and in this context it performs. Both the CCI and the CirCom score improved the performance of the model over using just demographic information, emphasizing the importance of including a comorbidity measure in any comparative study of cirrhosis survival. In particular, this validation study supports the use of the CirCom score as a measure of non-cirrhosis-related or all-cause mortality in cirrhotic patients in the English population.

The importance of our work is not just that it shows the utility of the score in an international context beyond Denmark, but that it also shows that the score is translatable into other coding systems such as the Read codes used in the CPRD. Furthermore, the Danish data use secondary care outpatient data for longitudinal comorbidity coding, whereas the English data use both linked inpatient secondary care and general practitioner primary care comorbidity coding. The finding that the score showed a consistent improvement over the CCI in this different health care context confirms the score's generalizability, particularly as we demonstrated an even greater improvement in the C statistic than in the original Danish derivation cohort.

The strengths of this study are that it provides an in-depth analysis of the performance of the CirCom score and the CCI in an English population. The English CPRD has extensive linkages, and these have allowed the current cohort to be validated and its characteristics comprehensively described.[@b1-clep-10-107],[@b9-clep-10-107],[@b10-clep-10-107] Therefore, we are confident of the validity of the cirrhosis diagnosis from the primary and secondary care data, and the recording of death from the national death registry. Furthermore, the recording of comorbidity in the CPRD has previously been validated against anonymized case records in many studies (myocardial infarction,[@b19-clep-10-107],[@b20-clep-10-107] heart failure,[@b21-clep-10-107],[@b22-clep-10-107] cerebrovascular disease,[@b23-clep-10-107]--[@b25-clep-10-107] dementia,[@b26-clep-10-107],[@b27-clep-10-107] respiratory disease,[@b28-clep-10-107]--[@b30-clep-10-107] connective tissue disease,[@b31-clep-10-107]--[@b34-clep-10-107] peptic ulcers,[@b35-clep-10-107] liver disease,[@b9-clep-10-107],[@b36-clep-10-107] renal failure,[@b37-clep-10-107] cancer,[@b38-clep-10-107] leukemia, and lymphoma[@b39-clep-10-107]), and the sensitivity of definitions improved when defined from linked primary and secondary care records (eg, diabetes,[@b40-clep-10-107],[@b41-clep-10-107] cirrhosis,[@b9-clep-10-107] and acute myocardial infarction[@b42-clep-10-107]).

The Model for End-Stage Liver Disease and the Child-Pugh score outperformed both the CCI and the CirCom score in predicting cirrhosis survival in a US Veteran cohort,[@b43-clep-10-107] and the validation in the original CirCom score paper showed the same.[@b6-clep-10-107] However, these measures depend on laboratory values that were not available in the CPRD. We have previously shown that it was possible to derive a measure of cirrhosis stage using just diagnostic coding within the CPRD,[@b9-clep-10-107] and including this as a variable for decompensation in our current study greatly improved the discrimination for liver-related death, and consequently the overall discrimination of all-cause mortality for our model with the CirCom score. The value of a comorbidity score, therefore, is that it predicts the additional non-liver-related outcomes that are not predicted by measures of severity of cirrhosis, and it will have benefit when added to any measure of cirrhosis severity.

The higher prevalence of comorbidity in the English cohort compared to the Danish cohort might reflect the more extensive comorbidity coding in a comprehensive primary care system in the UK or might reflect the more varied etiology of the English cohort, which had a lower proportion with alcohol etiology. We have previously shown that those patients with a non-alcohol etiology survive longer than those with an alcohol etiology, and, therefore, will have had a longer period of care in which to develop comorbidities and non-liver-related deaths.[@b44-clep-10-107] Finally, within the English cohort, the improvement with the CirCom score over the CCI was most noticeable in younger patients and in those with an alcohol etiology. This likely reflects the inclusion of epilepsy and substance abuse that have more importance in a cirrhotic cohort because of their association with a more hazardous lifestyle.[@b45-clep-10-107]

Conclusion
==========

We have validated the CirCom score in the English-linked CPRD as a measure of the burden of comorbidity and found that its performance is better than the CCI. However, both the CCI and the CirCom score improved discrimination compared to a model containing only age and sex. This emphasizes the importance of including any measure of comorbidity in comparative studies of cirrhosis survival.

Supplementary materials
=======================

###### 

Calibration plots for observed 1-year mortality from Kaplan--Meier estimates against predicted 1-year mortality from the Cox proportional hazards model from the (**A**) Charlson Comorbidity Index and (**B**) CirCom score.

**Note:** Calculated using the stcoxgrp ado program.[@b48-clep-10-107]

###### 

Decision curve analysis plots for (**A**) the Charlson Comorbidity Index and (**B**) the CirCom score.

**Note:** Calculated using the dca ado program.[@b49-clep-10-107]

###### 

Read code list for non-alcohol substance misuse

  Read code   Description
  ----------- ---------------------------------------------------------------------------------------------------------
  146C.00     Failed heroin detoxification
  146E.00     H/O: recreational drug use
  146F.00     H/O: drug abuse
  1J1.00      Suspected drug abuse
  1J10.00     Suspected abuse soft drugs
  1J11.00     Suspected abuse hard drugs
  1T.00       History of substance misuse
  1T0.00      H/O heroin misuse
  1T00.00     H/O daily heroin misuse
  1T01.00     H/O weekly heroin misuse
  1T02.00     Previous history of heroin misuse
  1T03.00     H/O infrequent heroin misuse
  1T1.00      H/O methadone misuse
  1T10.00     H/O daily methadone misuse
  1T11.00     H/O weekly methadone misuse
  1T13.00     Previous history of methadone misuse
  1T2.00      H/O ecstasy misuse
  1T20.00     H/O daily ecstasy misuse
  1T21.00     H/O weekly ecstasy misuse
  1T22.00     H/O infrequent ecstasy misuse
  1T23.00     Previous history of ecstasy misuse
  1T3.00      H/O benzodiazepine misuse
  1T30.00     H/O daily benzodiazepine misuse
  1T31.00     H/O weekly benzodiazepine misuse
  1T32.00     H/O infrequent benzodiazepine misuse
  1T33.00     Previous history of benzodiazepine misuse
  1T4.00      H/O amphetamine misuse
  1T40.00     H/O daily amphetamine misuse
  1T41.00     H/O weekly amphetamine misuse
  1T42.00     H/O infrequent amphetamine misuse
  1T43.00     Previous history of amphetamine misuse
  1T5.00      H/O cocaine misuse
  1T50.00     H/O daily cocaine misuse
  1T51.00     H/O weekly cocaine misuse
  1T52.00     H/O infrequent cocaine misuse
  1T53.00     Previous history of cocaine misuse
  1T6.00      H/O crack cocaine misuse
  1T60.00     H/O daily crack cocaine misuse
  1T61.00     H/O weekly crack cocaine misuse
  1T62.00     H/O infrequent crack cocaine misuse
  1T63.00     Previous history of crack cocaine misuse
  1T7.00      H/O hallucinogen misuse
  1T73.00     Previous history of hallucinogen misuse
  1T8.00      H/O cannabis misuse
  1T80.00     H/O daily cannabis misuse
  1T81.00     H/O weekly cannabis misuse
  1T82.00     H/O infrequent cannabis misuse
  1T83.00     Previous history of cannabis misuse
  1T9.00      H/O solvent misuse
  1T90.00     H/O daily solvent misuse
  1T91.00     H/O weekly solvent misuse
  1T93.00     Previous history of solvent misuse
  1TA.00      H/O barbiturate misuse
  1TB0.00     H/O daily major tranquilizer misuse
  1TD.00      H/O opiate misuse
  1TD0.00     H/O daily opiate misuse
  1TD1.00     H/O weekly opiate misuse
  1TD2.00     H/O infrequent opiate misuse
  1TD3.00     Previous history of opiate misuse
  1TE.00      Uses heroin on top of substitution therapy
  1TF.00      Does not use heroin on top of substitution therapy
  1V.00       Drug misuse behavior
  1V0.00      Misuses drugs
  1V00.00     Occasional drug user
  1V01.00     Long-term drug misuser
  1V02.00     Poly-drug misuser
  1V0C.00     Drug addict
  1V0E.00     Health problem secondary to drug misuse
  1V26.00     Misused drugs in past
  1V3.00      Drug injection behavior
  1V38.00     Sharing of drug-injecting equipment
  1V6.00      Drug-related offending behavior
  1V64.00     Illicit drug use
  1V65.00     Heroin misuse
  1V66.00     Ecstasy misuse
  46Q5.00     Urine amphetamine
  46Q5.11     Amphetamine in urine
  46QA.00     Urine cocaine
  63C6.00     Maternal drug abuse
  8AA.00      Drug abuse monitoring
  8H7x.00     Referral to drug abuse counselor
  8HHL.00     Referral to community drug dependency team
  8Hh1.00     Self-referral to substance misuse service
  E240.11     Heroin dependence
  E242.00     Cocaine type drug dependence
  E242000     Cocaine dependence, unspecified
  E242100     Cocaine dependence, continuous
  E242200     Cocaine dependence, episodic
  E242300     Cocaine dependence in remission
  E242z00     Cocaine drug dependence NOS
  E244.00     Amphetamine or other psychostimulant dependence
  E244000     Amphetamine or psychostimulant dependence, unspecified
  E244100     Amphetamine or psychostimulant dependence, continuous
  E244200     Amphetamine or psychostimulant dependence, episodic
  E244300     Amphetamine or psychostimulant dependence in remission
  E244z00     Amphetamine or psychostimulant dependence NOS
  E25.00      Nondependent abuse of drugs
  E256.00     Nondependent cocaine abuse
  E256000     Nondependent cocaine abuse, unspecified
  E256100     Nondependent cocaine abuse, continuous
  E256200     Nondependent cocaine abuse, episodic
  E256300     Nondependent cocaine abuse in remission
  E256z00     Nondependent cocaine abuse NOS
  E257.00     Nondependent amphetamine or other psychostimulant abuse
  E257000     Nondependent amphetamine/psychostimulant abuse, unspecified
  E257100     Nondependent amphetamine/psychostimulant abuse, continuous
  E257200     Nondependent amphetamine or psychostimulant abuse, episodic
  E257300     Nondependent amphetamine/psychostimulant abuse in remission
  E257z00     Nondependent amphetamine or psychostimulant abuse NOS
  E259.00     Nondependent mixed drug abuse
  E259000     Nondependent mixed drug abuse, unspecified
  E259100     Nondependent mixed drug abuse, continuous
  E259200     Nondependent mixed drug abuse, episodic
  E259300     Nondependent mixed drug abuse in remission
  E259z00     Nondependent mixed drug abuse NOS
  E25y.00     Nondependent other drug abuse
  E25y000     Nondependent other drug abuse, unspecified
  E25y100     Nondependent other drug abuse, continuous
  E25y200     Nondependent other drug abuse, episodic
  E25y300     Nondependent other drug abuse in remission
  E25yz00     Nondependent other drug abuse NOS
  Eu11212     Heroin addiction
  Eu14.00     Mental and behavioral disorders due to use of cocaine
  Eu14000     Mental and behavior disorder due to use cocaine: acute intoxication
  Eu14100     Mental and behavior disorder due to use of cocaine: harmful use
  Eu14200     Mental and behavior disorder due to use of cocaine: dependence syndrome
  Eu14211     Drug addiction -- cocaine
  Eu14300     Mental and behavior disorder due to use of cocaine: withdrawal state
  Eu14500     Mental and behavior disorder due to use of cocaine: psychotic disorder
  Eu1A.00     Mental and behavioral disorders due to use of crack cocaine
  Eu1A000     Mental and behavioral disorders due to use of crack cocaine: acute intoxication
  Eu1A100     Mental and behavioral disorders due to use of crack cocaine: harmful use
  Eu1Az00     Mental and behavioral disorders due to use of crack cocaine: unspecified mental and behavioral disorder
  R10B000     Finding of cocaine in blood
  SL50100     Heroin poisoning
  SL85000     Cocaine poisoning
  TJ85000     Adverse reaction to cocaine
  U205.11     Overdose -- heroin
  U608312     Adverse reaction to cocaine
  Z1Q6214     Heroin maintenance
  ZC16.00     Abuse of drugs to lose weight
  ZV11500     Personal history of drug abuse by injection
  ZV6D700     Drug abuse counseling and surveillance

**Abbreviations:** H/O, history of; NOS, not otherwise specified.

###### 

Socioeconomic status (as per IMD 2010)-stratified discrimination of the comorbidity models

  Quintile of socioeconomic status   Patients (n)   Patients (%)   Charlson Comorbidity Index C statistic   95% CI       CirCom index C statistic                              95% CI
  ---------------------------------- -------------- -------------- ---------------------------------------- ------------ ----------------------------------------------------- ------------
  Missing socioeconomic status       19             0.00           0.71                                     0.48--0.94   0.62                                                  0.36--0.88
  1=least deprived                   856            0.17           0.63                                     0.60--0.66   0.64[\*](#tfn13-clep-10-107){ref-type="table-fn"}     0.62--0.67
  2                                  987            0.19           0.65                                     0.62--0.67   0.64                                                  0.62--0.67
  3                                  986            0.19           0.61                                     0.59--0.64   0.62                                                  0.60--0.65
  4                                  1059           0.21           0.60                                     0.58--0.63   0.62                                                  0.59--0.64
  5=most deprived                    1211           0.24           0.61                                     0.59--0.63   0.63[\*\*](#tfn14-clep-10-107){ref-type="table-fn"}   0.61--0.65

**Notes:**

*p*=0.03 between discrimination for the Charlson Comorbidity Index and the CirCom score.

*p*=0.007 between discrimination for the Charlson Comorbidity Index and the CirCom score. IMD, *The English Indices of Multiple Deprivation 2010*.[@b47-clep-10-107]

**Abbreviation:** CI, confidence interval.
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###### 

A comparison of the patient demographics of the Clinical Practice Research Datalink (CPRD) validation cohort and the original Danish Patient Registry derivation cohort

  Characteristics of the validation cohort   CPRD cirrhosis cohort   Danish patient registry cohort            
  ------------------------------------------ ----------------------- -------------------------------- -------- ------------
  Number of patients                         5,118                                                    12,976   
  Follow-up time (person years)              14,438                                                   40,847   
  Deaths during follow-up                    2564                    50.1                             8911     68.7
  Median follow-up time (years)              1.9                                                      2.8      
  1-year mortality                           1516                    29.6                                      34.5
  5-year mortality                           2332                    45.6                                      80.5
  Mean age (interquartile range)             59.1                    49.4--70.0                       57.9     50.3--65.3
  Female                                     2153                    42.1                             4397     33.9
  Male                                       2965                    57.9                             8579     66.1
  Decompensated at presentation              2235                    43.7                                      
  **Etiology**                                                                                                 
  Alcohol                                    2756                    53.9                                      73.7
  Viral/autoimmune/metabolic                 1079                    21.1                                      
  Unknown                                    1283                    25.1                                      
  **Most prevalent comorbidities**                                                                             
  Diabetes without complications             979                     19.1                             835      6.4
  Rheumatological disease                    705                     13.8                             422      3.3
  Chronic obstructive pulmonary disease      445                     8.7                              951      7.3
  Congestive cardiac disease                 344                     6.7                              673      5.2
  Cerebrovascular disease                    256                     5.0                              720      5.5
  Diabetes with complications                252                     4.9                              813      6.3
  Hypothyroidism                             250                     4.9                                       
  Peptic ulcer disease                       239                     4.7                              1579     12.2
  Cerebrovascular disease                    234                     4.6                              720      5.5
  Renal disease                              231                     4.5                              67       0.5
  **CirCom score**                                                                                             
  0                                          3120                    61.0                             9841     75.8
  1+0                                        1384                    27.0                             2143     16.5
  1+1                                        409                     8.0                              477      3.7
  3+0                                        56                      1.1                              313      2.4
  3+1                                        147                     2.9                              136      1.0
  5+0                                        2                       0.0                              50       0.4
  5+1                                        0                       0                                16       0.1
  **Charlson Comorbidity Index**                                                                               
  0                                          2644                    51.7                             7477     57.6
  1                                          999                     19.5                             3034     23.4
  2                                          617                     12.1                             1422     11.0
  3                                          299                     5.8                              576      4.4
  4                                          200                     3.9                              208      1.6
  5                                          108                     2.1                              80       0.6
  6                                          74                      1.5                              106      0.8
  ≥7                                         177                     3.5                              73       0.6

**Note:** Cells are left blank where information was not presented in the papers on the original cohort studies.

###### 

Full models with the comorbidity scores in the Clinical Practice Research Datalink validation cohort

  Covariate                        Charlson Comorbidity Index   Covariate     CirCom score                                      
  -------------------------------- ---------------------------- ------------- -------------- ---------------------------------- -------------
  \<20 years                       Reference                    --                           Reference                          --
  20--29 years                     2.43                         0.58--10.26                  1.90                               0.45--8.03
  30--39 years                     2.56                         0.63--10.37                  2.06                               0.51--8.34
  40--49 years                     3.26                         0.81--13.08                  2.66                               0.66--10.68
  50--59 years                     3.66                         0.91--14.68                  3.11                               0.78--12.47
  60--69 years                     4.01                         1.00--16.06                  3.63                               0.90--14.54
  70--79 years                     5.74                         1.43--23.03                  5.27                               1.31--21.12
  80--89 years                     8.10                         2.02--32.57                  7.22                               1.80--29.05
  90--99 years                     13.89                        3.26--59.14                  10.80                              2.54, 46.01
  Female                           Reference                    --                           Reference                          --
  Male                             1.28                         1.18--1.39                   1.24                               1.15--1.35
  **Charlson Comorbidity Index**                                                             **CirCom score**                   
  0                                Reference                    --            0              Reference                          --
  1                                1.09                         0.98--1.21    1+0            1.43                               1.31--1.57
  2                                1.27                         1.12--1.43    1+1            1.88                               1.64--2.15
  3                                1.53                         1.31--1.79    3+0            2.29                               1.67--3.14
  4                                1.46                         1.20--1.77    3+1            2.95                               2.44--3.56
  5                                1.63                         1.27--2.09    5+0            13.00                              3.24--52.24
  6                                1.62                         1.21--2.17    5+1            No patients with a score of 5 +1   
  7                                1.98                         1.37--2.87                                                      
  8                                3.09                         2.40--3.98                                                      
  9                                4.21                         2.73--6.50                                                      
  10                               5.22                         2.94--9.25                                                      
  11                               4.23                         2.39--7.50                                                      
  12                               1.70                         0.55--5.29                                                      
  13                               4.95                         2.05--11.99                                                     
  15                               4.46                         0.63--31.74                                                     
  Total patients (N)               5118                                                      5118                               
  BIC                              40434                                                     40294                              

**Note:** Exponentiated coefficients.

**Abbreviations:** BIC, Bayesian information criterion; CI, confidence interval.

###### 

Discrimination of the comorbidity models

  Measured parameter                                                Age and sex   Age and sex + Charlson Comorbidity Index   Age and sex + CirCom score
  ----------------------------------------------------------------- ------------- ------------------------------------------ ----------------------------
  **C statistic**                                                   0.60          0.62                                       0.63
  95% CIs                                                           0.59--0.61    0.61--0.63                                 0.62--0.64
  **Mean 1-year predicted mortality risk**                                                                                   
  1-year predicted mortality risk in patients who survived          28.6%         27.8%                                      27.7%
  1-year predicted mortality risk in patients who died              33.4%         35.1%                                      35.3%
  **Net reclassification index (NRI) (£20%, 21%**--**50%, ≥51%**)                                                            
  NRI (compared to age and sex)                                     NA            6.4%                                       8.0%
  NRI (CirCom versus Charlson index)                                NA            NA                                         1.5%

**Abbreviation:** CI, confidence interval; NA, not applicable.

###### 

Age-stratified discrimination of the comorbidity models

  Age (years)   Patients (n)   Patients (%)   Charlson Comorbidity Index C statistic   95% CI       CirCom score C statistic   95% CI
  ------------- -------------- -------------- ---------------------------------------- ------------ -------------------------- ------------
  \<45          827            16             0.58                                     0.54--0.61   0.62                       0.59--0.66
  45--54        1182           23             0.54                                     0.52--0.57   0.56                       0.54--0.59
  55--64        1300           25             0.57                                     0.54--0.59   0.58                       0.56--0.61
  65--74        991            19             0.60                                     0.57--0.62   0.60                       0.58--0.63
  \>74          818            16             0.57                                     0.54--0.59   0.56                       0.53--0.58

**Notes:** Each estimate is also adjusted for gender.

**Abbreviation:** CI, confidence interval.

###### 

Etiology- and compensation-stratified discrimination of the comorbidity models

  Cirrhosis etiology or compensation state at start of study   Patients (n)   Patients (%)   Charlson Comorbidity Index C statistic   95% CI       CirCom score C statistic   95% CI
  ------------------------------------------------------------ -------------- -------------- ---------------------------------------- ------------ -------------------------- ------------
  Alcohol                                                      2756           54             0.57                                     0.56--0.59   0.59                       0.57--0.60
  Other[a](#tfn7-clep-10-107){ref-type="table-fn"}             1079           21             0.64                                     0.61--0.67   0.65                       0.62--0.67
  Unknown                                                      1283           25             0.69                                     0.67--0.71   0.69                       0.67--0.71
  Compensated                                                  2883           56             0.63                                     0.62--0.65   0.65                       0.63--0.66
  Decompensated                                                2235           44             0.62                                     0.60--0.63   0.62                       0.60--0.64

**Notes:**

Autoimmune, viral, or metabolic. Each estimate is also adjusted for age and gender.

**Abbreviation:** CI, confidence interval.

###### 

Follow-up-stratified discrimination of the comorbidity models

  Age band     Patients (n)   Person years   Charlson Comorbidity Index C statistic   95% CI       CirCom score C statistic   95% CI
  ------------ -------------- -------------- ---------------------------------------- ------------ -------------------------- ------------
  \<1 year     5118           1320183        0.62                                     0.61--0.64   0.64                       0.62--0.65
  1--2 years   2963           2019508        0.62                                     0.58--0.65   0.59                       0.56--0.62
  2--3 years   2194           2297575        0.63                                     0.59--0.66   0.65                       0.61--0.69
  3--4 years   1639           2315506        0.63                                     0.58--0.68   0.63                       0.59--0.68
  4--5 years   1217           2163567        0.63                                     0.58--0.70   0.61                       0.56--0.67

**Notes:** Each estimate is also adjusted for age and gender.

**Abbreviation:** CI, confidence interval.

###### 

Cause of death--stratified and compensation-stratified discrimination of the comorbidity models

  Cause of death            Patients (n)       Patients (%)       Charlson Comorbidity Index C statistic    95% CI       CirCom score C statistic                  95% CI
  ------------------------- ------------------ ------------------ ----------------------------------------- ------------ ----------------------------------------- ------------
  Liver-related death       1301               25                 0.56                                      0.54--0.57   0.56                                      0.54--0.57
  Non-liver-related death   1263               25                 0.72                                      0.71--0.74   0.72                                      0.71--0.74
                                                                                                                                                                   
  **Cause of death**        **Patients (n)**   **Patients (%)**   **Including measure of decompensation**   **95% CI**   **Including measure of decompensation**   **95% CI**
                                                                                                                                                                   
  Liver-related death       1301               25                 0.64                                      0.63--0.66   0.64                                      0.63--0.66
  Non-liver-related death   1263               25                 0.73                                      0.72--0.75   0.73                                      0.72--0.75

**Abbreviation:** CI, confidence interval.
